文献速递消化系统肿瘤

泛免疫炎症值在微卫星高度不稳定转移性结直肠癌免疫治疗中的预后价值

The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
PubMed 文献 · Eur J Cancer · 2021-04-24

该回顾性研究纳入163例接受PD-(L)1±CTLA-4抑制剂治疗的MSI-H转移性结直肠癌患者,评估泛免疫炎症值(PIV)及其早期变化与疗效的关系。多因素分析显示,高基线PIV(>492)和早期PIV升高≥30%均独立预测更差的总生存和无进展生存,早期PIV升高还可独立预测临床获益。

要点

  • 高基线PIV(>492)与MSI-H mCRC患者免疫治疗后更差OS和PFS独立相关。
  • 治疗早期PIV升高≥30%独立预测更差OS、PFS及更低临床获益。
  • 高PIV患者接受抗PD-1/PD-L1单药治疗时OS和PFS显著更差。

核心结论

  • PIV是接受ICIs治疗的MSI-H mCRC患者结局的强预测因子,需前瞻性验证其作为分层因素的作用。

研究设计与样本

  • 回顾性分析163例接受抗PD-(L)1±抗CTLA-4治疗的MSI-H mCRC患者,计算PIV并评估其与结局的关联。

主要发现

  • 高基线PIV(>492)与更差OS独立相关(aHR 3.00,95%CI 1.49-6.04,p=0.002)和更差PFS独立相关(aHR 1.91,95%CI 1.06-3.44,p=0.031)。
  • 早期PIV升高≥30%与更差OS独立相关(aHR 3.21,95%CI 1.65-6.23,p<0.001)和更差PFS独立相关(aHR 2.25,95%CI 1.30-3.89,p=0.003)。
  • 早期PIV升高是临床获益的独立预测因素(aOR 0.23,95%CI 0.08-0.66,p=0.007),基线PIV仅显示趋势(aOR 0.33,95%CI 0.10-1.07,p=0.065)。
  • 按基线PIV和ICI方案分层后,高PIV且接受抗PD-1/PD-L1单药治疗的患者OS和PFS显著更差。

关键数值与推荐

  • PIV计算公式为(中性粒细胞计数×血小板计数×单核细胞计数)/淋巴细胞计数。
  • PIV截断值通过最大选择秩统计量确定,高基线PIV定义为>492。
  • 早期PIV升高定义为治疗开始后3/4周时较基线升高≥30%。

临床怎么用

  • 基线PIV和早期PIV变化可能辅助识别MSI-H mCRC免疫治疗预后不良或原发耐药患者。
  • 高PIV患者接受免疫单药治疗时结局更差,或需考虑联合策略但尚待前瞻性验证。

局限性

  • 回顾性研究设计,结果需前瞻性验证。
  • PIV截断值由最大选择秩统计量确定,可能存在过拟合风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) yielded unprecedented efficacy in patients with microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). Since the Pan-Immune-Inflammation Value (PIV) is a blood-based biomarker with prognostic usefulness in mCRC, it might predict clinical outcomes and primary resistance to ICIs. METHODS: We retrospectively analysed the association of PIV and its early modulation at 3/4 weeks after treatment initiation with the outcomes of MSI-high mCRC patients receiving anti-programmed death-(ligand)1 (PD-[L]1) +/- anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) agents. PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. PIV cut-offs were determined using the maximally selected rank statistics. RESULTS: A total of 163 patients were included. In the multivariable models for overall survival (OS) and progression-free survival (PFS), both high (>492) baseline PIV (OS: adjusted [a] HR, 3.00; 95% CI, 1.49-6.04, p = 0.002; PFS: aHR, 1.91; 95% CI, 1.06-3.44, p = 0.031) and early PIV increase ≥+30% (OS: aHR, 3.21; 95% CI, 1.65-6.23, p < 0.001; PFS: aHR, 2.25; 95% CI, 1.30-3.89, p = 0.003) confirmed an independent prognostic impact. After stratifying patients according to baseline PIV and ICI regimen, OS and PFS were significantly worse in subjects with high PIV receiving anti-PD-1/PD-L1 monotherapy. Early PIV increase was an independent predictor of clinical benefit (aOR, 0.23; 95% CI, 0.08-0.66; p = 0.007), whereas a trend was observed for baseline PIV (aOR, 0.33; 95% CI, 0.10-1.07; p = 0.065). CONCLUSION: PIV is a strong predictor of outcomes in MSI-high mCRC patients receiving ICIs. Prospective validation of these results is required to establish its role as a stratification factor for personalised combination strategies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Corti F, Lonardi S, Intini R, et al. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021. PMID: 33901794. doi:10.1016/j.ejca.2021.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。